Hypolipidemic Agents

"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.

Descriptor ID	D000960
MeSH Number(s)	D27.505.519.186.071 D27.505.954.557.500
Concept/Terms	Hypolipidemic Agents Hypolipidemic Agents Agents, Hypolipidemic Antihyperlipidemics Hypolipidemic Drugs Drugs, Hypolipidemic Antilipemic Drugs Drugs, Antilipemic Antilipemics Antihyperlipemics Antilipemic Agents Agents, Antilipemic

Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]

Below are MeSH descriptors whose meaning is related to "Hypolipidemic Agents".

Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.

Bar chart showing 38 publications over 20 distinct years, with a maximum of 5 publications in 2003 and 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2002	1	1	2
2003	3	2	5
2004	1	1	2
2005	1	1	2
2006	2	3	5
2007	0	1	1
2008	2	0	2
2009	1	2	3
2010	1	0	1
2011	2	1	3
2013	2	0	2
2014	1	0	1
2015	1	0	1
2017	0	1	1
2018	0	1	1
2019	1	1	2
2020	0	1	1
2022	0	1	1
2024	0	1	1

Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.

Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun; 18(3):e308-e319.

View in: PubMed
Patrick WL, Khurshan F, Bavaria JE, Zhao Y, Groeneveld PW, Yarlagadda S, Rosen JL, Grimm JC, Szeto WY, Desai ND. National Adherence to Medical Management of Aortic Aneurysms. Am J Med. 2022 10; 135(10):1202-1212.e4.

View in: PubMed
Mintzer S, Yi M, Hegarty S, Maio V, Keith S. Hyperlipidemia in patients newly treated with anticonvulsants: A population study. Epilepsia. 2020 02; 61(2):259-266.

View in: PubMed
Khan SU, Khan MU, Valavoor S, Khan MS, Okunrintemi V, Mamas MA, Leucker TM, Blaha MJ, Michos ED. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2020 08; 27(12):1255-1268.

View in: PubMed
Wright AK, Kontopantelis E, Emsley R, Buchan I, Mamas MA, Sattar N, Ashcroft DM, Rutter MK. Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus: A Population-Based Cohort Study Assessing Sex Disparities Circulation. 2019 06 11; 139(24):2742-2753.

View in: PubMed
Robinson JG, Williams KJ, Gidding S, Bor?n J, Tabas I, Fisher EA, Packard C, Pencina M, Fayad ZA, Mani V, Rye KA, Nordestgaard BG, Tybj?rg-Hansen A, Douglas PS, Nicholls SJ, Pagidipati N, Sniderman A. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc. 2018 10 16; 7(20):e009778.

View in: PubMed
Skolnik N, Jaffa FM, Kalyani RR, Johnson E, Shubrook JH. Reducing CV risk in diabetes: An ADA update. J Fam Pract. 2017 May; 66(5):300-308.

View in: PubMed
Williams KH, Sullivan DR, Nicholson GC, George J, Jenkins AJ, Januszewski AS, Gebski VJ, Manning P, Tan YM, Donoghoe MW, Ehnholm C, Young S, O'Brien R, Buizen L, Twigg SM, Keech AC. Opposite associations between alanine aminotransferase and ?-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016 May; 65(5):783-793.

View in: PubMed
Karahanian E, Quintanilla ME, Fernandez K, Israel Y. Fenofibrate--a lipid-lowering drug--reduces voluntary alcohol drinking in rats. Alcohol. 2014 Nov; 48(7):665-70.

View in: PubMed
Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct; 44(10):2688-93.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement